Shots: Lexicon to receive $260M as termination fee including $208M upon signing the termination agreement and $52M is payable within 12mos. Lexicon regain global rights to develop & commercialize Zynquista […]readmore
Tags : sotagliflozin
Shots: The three P-III studies (SOTA-MET, SOTA-CKD3, SOTA-CKD4) involves assessing of Zynquista vs PBO in patients with T2D. The first two studies resulted in meeting its 1EPs i.e, @26wks. reduction […]readmore
Shots: The authorization is based on inTandem study consisting of three P-III trials assessing sotagliflozin (200/400 mg) vs insulin as monothx in 3000 adults with inadequately controlled T1D The study […]readmore
Regulatory
Sanofi’s Zynquista (sotagliflozin) and Dupixent (dupilumab) Receives CHMP Recommendation for
Shots: Zynquista’s CHMP recommendation is based on P-III TANDEM study assessing Zynquista (200mg &400mg) vs insulin in 3,000 patients with T1D mellitus. The study resulted in reduction in blood sugar […]readmore